Summary & Overview
HCPCS J9322: Pemetrexed (bluepoint) Injection, 10 mg
HCPCS Level II code J9322 identifies a 10 mg unit of pemetrexed (bluepoint), a chemotherapeutic agent billed as a drug supply item distinct from therapeutically equivalent products like J9305. This code matters nationally because accurate drug-level billing affects hospital outpatient and physician practice oncology reimbursement, inventory management, and claims processing for parenteral chemotherapy. Major payers relevant to this code include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise explanation of the code’s clinical and billing context, typical sites of service, and the implications for service lines that manage chemotherapy infusions. The publication provides benchmarks and coverage considerations for payers listed above, summarizes common modifier usage where applicable, and outlines operational impacts for infusion centers and oncology practices. It also highlights coding distinctions—specifically that J9322 is for a branded bluepoint pemetrexed product not considered therapeutically equivalent to J9305—which can influence prior authorization, billing accuracy, and reimbursement variance across payers. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9322 describes an injection of pemetrexed (bluepoint), 10 mg, specified as not therapeutically equivalent to J9305. This code represents the drug product and unit of measure for billing single-dose injectable pemetrexed supplied under the bluepoint brand.
-
Service type: Drug administration billed as a medication supply line item
-
Typical site of service: Hospital outpatient departments, physician offices, and infusion centers where chemotherapy and parenteral oncology agents are administered
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with newly diagnosed stage IV non-small cell lung cancer (NSCLC) presents to an outpatient infusion center for first-line systemic therapy. The oncology team prescribes pemetrexed as part of a chemotherapy regimen. The medication is supplied and billed as J9322 (pemetrexed, 10 mg unit). Prior to infusion, the patient undergoes standard premedication and laboratory testing including complete blood count, renal and hepatic panels to confirm eligibility and dosing. The medication is prepared by pharmacy under sterile technique and delivered to the ambulatory infusion suite. The infusion nurse verifies identity, reviews chemotherapy consent and administration orders, confirms baseline labs, documents supportive medications (eg, folic acid, vitamin B12, dexamethasone), and administers the pemetrexed per protocol. Billing captures the vial units by J9322, the infusion administration CPT(s), and any applicable modifiers to reflect physician involvement, split/shared services, or special circumstances (for example, drug waste reporting with modifier JW). Typical sites of service include hospital outpatient departments and free-standing oncology infusion centers. Patient monitoring includes routine vital signs and assessment for infusion reactions; follow-up appointments document response assessment and ongoing cycle planning.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|